Led · Equity · May 2024

Galileo Wheel develops and commercializes the CupWheel® tire technology for farming machinery. The company positions CupWheel as a once-in-a-generation technology leap for operators of farming equipment, aiming to make modern agriculture more sustainable. Galileo says CupWheel can help advance modern agriculture, improve crop yields, and foster a more sustainable future for farmers. The firm announced an $8M investment round led by Stine Seed Farm of Adel, Iowa. Stine Seed Farm, described as one of the largest privately held seed companies in the U.S. with over 40 years of expertise in corn and soybean genetics, will partner with Galileo. Galileo’s leadership framed the investment as validation and a strategic partnership to combine Stine’s genetics expertise with Galileo’s tire technology to accelerate sustainable farming innovation.

Led · Series B · May 2022

Vyriad engineers viruses, viral vectors, and envelope glycoproteins to deliver therapeutic genes directly to selected cells, eliminating the need for complex ex vivo manufacturing. Its proprietary lentiviral platform employs engineered G proteins to create highly specific, blood-stable vectors that can reprogram immune cells in the body, enabling scalable access to CAR-T therapies. Lead candidate VV169 combines an optimized lentiviral vector (LV-169) with a BCMA-directed CAR transgene and is slated to enter first-in-human Phase 1 testing in relapsed or refractory multiple myeloma patients. Preclinical data presented at ASH 2025 showed VV169 eliminated disseminated multiple myeloma in all tested humanized mouse models, even at the lowest dose. Future plans include advancing VV169 into the clinic in 2026 and validating the broader delivery platform for additional in vivo CAR-T programs. Vyriad also maintains corporate partnerships with Regeneron Pharmaceuticals and Novartis, supporting development across oncolytic virotherapy, in vivo gene therapy, and gene-editing applications. The company is privately held and headquartered in Rochester, Minnesota. To date, it has secured at least $85 million in Series B funding to fuel its ongoing clinical and platform development.